Alan Goldsobel, MD
Allergy & Immunology · San Jose, CANPI 1063528321
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,000 of the $66,438 with a category attached, or 63.2%. 33 manufacturers reported payments, led by GSK at 45.1% of the total. Reporting peaked in 2019 at $20,371 and has fallen 80.7% since, to $3,936 in 2025. Among allergy & immunology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $190.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$30K
- Optinose US, Inc.$17K
- Merck$7K
- AstraZeneca$5K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $5K from 27 others
Across 588 payments — averaging $5496.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$746K
- AstraZeneca$486K
- Sanofi US Services Inc.$440K
- GSK$423K
- Teva Pharmaceuticals USA, Inc.$372K
- Cipla USA Inc.$250K
- plus $513K from 5 others
What the payments were for
- Consulting fees$12,02418%
- Speaking & faculty fees$42,00063%
- Travel & lodging$4,0366%
- Food & beverage$8,08312%
- Education$2960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 98 | $29,958 |
| Optinose US, Inc. | 34 | $17,121 |
| Merck | 5 | $6,596 |
| AstraZeneca | 76 | $5,083 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $1,559 |
| Regeneron Healthcare Solutions, Inc. | 6 | $1,399 |
| Octapharma USA, Inc. | 7 | $1,208 |
| CSL Behring | 22 | $617 |
| Sanofi | 12 | $553 |
| Genentech USA, Inc. | 6 | $225 |
| Teva Pharmaceuticals USA, Inc. | 5 | $192 |
| Alk-abello, Inc | 5 | $192 |
| Novartis | 11 | $183 |
| Sanofi-aventis U.S. LLC | 3 | $177 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $173 |
| Ionis Pharmaceuticals, Inc. | 2 | $143 |
| Boehringer Ingelheim | 8 | $133 |
| Kaleo, Inc. | 3 | $120 |
| Pharming Healthcare, Inc. | 5 | $119 |
| Amgen(2 entities) | 4 | $116 |
| Pfizer | 7 | $115 |
| Grifols USA, LLC | 5 | $114 |
| Regeneron | 3 | $64 |
| Blueprint Medicines Corporation | 1 | $42 |
| Covis Pharma GmbH | 2 | $41 |
| Galderma Laboratories, L.p. | 1 | $31 |
| Biocryst US Sales Co., LLC | 1 | $30 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Circassia Inc. | 1 | $25 |
| Hospira, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Philips North America LLC | 1 | $22 |
| USWM, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$66,438 in reported general payments places this provider in the 90th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 39 | $154,782 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $146,113 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $111,300 |
| Dupixent SyringeDupilumab | 26 | $98,257 |
| XolairOmalizumab | 22 | $76,196 |
| NucalaMepolizumab | 13 | $49,310 |
| DuleraMometasone/Formoterol | 46 | $22,591 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $21,332 |
| Azelastine Hcl | 150 | $7,522 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $7,105 |
| Arnuity ElliptaFluticasone Furoate | 13 | $6,436 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $5,284 |
| Advair DiskusFluticasone Propion/Salmeterol | 14 | $5,283 |
| Ipratropium Bromide | 93 | $4,369 |
| Pulmicort FlexhalerBudesonide | 13 | $4,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $29,958 | $188,378178 claims |
| CSL BehringHizentra | $617 | $146,11314 claims |
| MerckDulera | $6,596 | $22,59146 claims |
| Hikma Pharmaceuticals USARyaltris, Epinephrine | $28 | $5,20430 claims |
| AstraZenecaPulmicort Flexhaler | $5,083 | $4,33613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in San Jose
- James WolfeSan Jose$178K
- Robert TorranoSan Jose$57K
- Raffi TachdjianSanta Monica$3.7M
- Bob GengSan Diego$3.3M
- Vinay MehtaLaguna Niguel$1.3M
- Andrew WhiteSan Diego$752K
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Brian Modenala Jolla$453K
- Heena Shah PatelUpland$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.